GSPT1 and glioblastoma: Although GSPT1-selective immunomodulatory drugs and other drugs/molecules that decrease GSPT1 levels via pathways other than the CRL4CBRN pathway may be promising candidates for glioblastoma and other types of tumors, GSPT1 possesses a potential weak point, and can cause unexpected consequences via its functions as a translational terminator.